+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Urothelial Cancer Drugs Market by Therapy Type, Mechanism, Line Of Therapy, Stage, Administration Route, Treatment Setting - Global Forecast to 2030- Product Image
Urothelial Cancer Drugs Market by Therapy Type, Mechanism, Line Of Therapy, Stage, Administration Route, Treatment Setting - Global Forecast to 2030- Product Image
Sale

Urothelial Cancer Drugs Market by Therapy Type, Mechanism, Line Of Therapy, Stage, Administration Route, Treatment Setting - Global Forecast to 2030

  • PDF Icon

    Report

  • 195 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5889233
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Urothelial Cancer Drugs Market is experiencing a period of rapid innovation driven by the growing disease burden, the shift toward precision medicine, and evolving commercial and policy landscapes. Intensifying competition, technological advances, and regional policy shifts are shaping opportunities for stakeholders across the pharmaceutical value chain.

Market Snapshot: Urothelial Cancer Drugs Market Overview

The Urothelial Cancer Drugs Market grew from USD 3.47 billion in 2024 to USD 3.82 billion in 2025. It is expected to continue growing at a CAGR of 9.95%, reaching USD 6.14 billion by 2030. This robust trajectory is fueled by increasing prevalence rates, optimization of healthcare delivery models, and advancement of novel product classes. The adoption of immuno-oncology, improved diagnostics, and global investment accelerates the shift in clinical treatment paradigms across both developed and emerging economies.

Scope & Segmentation

  • Therapy Types: Antibody drug conjugates (including Nectin-4 targeted), broad chemotherapy classes, immunotherapies (PD-1 and PD-L1 inhibitors such as nivolumab, pembrolizumab, atezolizumab, and durvalumab), and targeted therapies (such as FGFR inhibitors).
  • Mechanisms: FGFR inhibition (e.g., erdafitinib), Nectin-4 targeting (enfortumab vedotin), PD-1 inhibition, PD-L1 inhibition.
  • Line of Therapy: First line, second line, and third line or later treatment options.
  • Disease Stage: Metastatic, muscle-invasive, and non-muscle-invasive urothelial carcinoma segments.
  • Administration Routes: Intravenous and oral modalities catering to varied patient and provider preferences.
  • Treatment Settings: Delivery across hospitals, oncology centers, and outpatient clinics, informing resource planning and patient access strategies.
  • Regions Covered: Americas (with detailed analysis of key U.S. states), Europe, Middle East & Africa (including Western and emerging markets), Asia-Pacific (from established markets like Japan and Australia to rapidly growing segments in China and India).
  • Key Companies: Merck & Co., Inc., Roche Holding AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Pfizer Inc., Merck KGaA, Johnson & Johnson, Astellas Pharma Inc., Seagen Inc., and Gilead Sciences, Inc.

Key Takeaways for Senior Decision-Makers

  • Emerging modalities, such as antibody drug conjugates and precision FGFR inhibitors, are transforming standard-of-care and enabling tailored therapy selection.
  • Market participants are responding to clinical needs and policy developments by intensifying investment in adaptive clinical trial designs, companion diagnostics, and real-world outcomes research.
  • Strategic focus on quality of life and patient-reported outcomes is influencing both trial endpoints and long-term adoption across healthcare systems.
  • The evolving competitive environment is marked by cross-industry alliances, robust patent strategies, and consolidation via mergers or joint ventures to accelerate scale and market access.
  • Regional market variations, including distinct regulatory environments in the Americas, EMEA, and Asia-Pacific, impact launch strategies, reimbursement, and localization requirements.

Tariff Impact

Recent U.S. tariffs on pharmaceutical inputs have increased manufacturing costs for urothelial cancer drugs, leading to new sourcing models and renegotiation of supply contracts. This shift is affecting R&D budgets, prioritizing late-stage assets and breakthrough therapies, while encouraging advocacy for tariff exemptions and partnerships that diversify supply chains. Such policy-driven changes are altering cost structures and prompting a reassessment of risk throughout the manufacturing and commercialization process.

Methodology & Data Sources

Market insights are based on a multi-phase research approach, including over 50 structured interviews with oncologists, senior pharma executives, payers, and key opinion leaders. Supplementary secondary research covered regulatory filings, clinical trial databases, peer-reviewed studies, and proprietary datasets. Data integrity was assured using triangulation and peer review, supporting actionable, validated findings tailored for strategic planning.

Why This Report Matters

  • Provides a comprehensive, segmented analysis of the urothelial cancer drug landscape, focusing on innovation, commercial models, and emerging technologies.
  • Enables informed, high-impact decisions for portfolio strategy, market entry, and risk mitigation in a rapidly evolving therapeutic area.
  • Supports resource allocation, supply chain planning, and partnership strategies with timely insights into regulatory, policy, and competitive developments.

Conclusion

This report equips senior leaders with clear, actionable intelligence to navigate the changing landscape of urothelial cancer therapeutics. Strategic engagement, operational resilience, and investment in quality will position stakeholders to capture value throughout the dynamic market cycle.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Urothelial Cancer Drugs Market, by Therapy Type
8.1. Introduction
8.2. Antibody Drug Conjugates
8.2.1. Nectin-4 Targeted
8.3. Chemotherapy
8.3.1. Non Platinum Based
8.3.2. Platinum Based
8.4. Immunotherapy
8.4.1. PD-1 Inhibitors
8.4.1.1. Nivolumab
8.4.1.2. Pembrolizumab
8.4.2. PD-L1 Inhibitors
8.4.2.1. Atezolizumab
8.4.2.2. Durvalumab
8.5. Targeted Therapy
8.5.1. FGFR Inhibitors
9. Urothelial Cancer Drugs Market, by Mechanism
9.1. Introduction
9.2. FGFR Inhibitors
9.2.1. Erdafitinib
9.3. Nectin-4 Targeted
9.3.1. Enfortumab Vedotin
9.4. PD-1 Inhibitors
9.4.1. Nivolumab
9.4.2. Pembrolizumab
9.5. PD-L1 Inhibitors
9.5.1. Atezolizumab
9.5.2. Durvalumab
10. Urothelial Cancer Drugs Market, by Line Of Therapy
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line Or Later
11. Urothelial Cancer Drugs Market, by Stage
11.1. Introduction
11.2. Metastatic
11.3. Muscle Invasive
11.4. Non Muscle Invasive
12. Urothelial Cancer Drugs Market, by Administration Route
12.1. Introduction
12.2. Intravenous
12.3. Oral
13. Urothelial Cancer Drugs Market, by Treatment Setting
13.1. Introduction
13.2. Hospital Infusion
13.3. Oncology Center
13.4. Outpatient Clinic
14. Americas Urothelial Cancer Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Urothelial Cancer Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Urothelial Cancer Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Merck & Co., Inc.
17.3.2. Roche Holding AG
17.3.3. AstraZeneca PLC
17.3.4. Bristol-Myers Squibb Company
17.3.5. Pfizer Inc.
17.3.6. Merck KGaA
17.3.7. Johnson & Johnson
17.3.8. Astellas Pharma Inc.
17.3.9. Seagen Inc.
17.3.10. Gilead Sciences, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. UROTHELIAL CANCER DRUGS MARKET MULTI-CURRENCY
FIGURE 2. UROTHELIAL CANCER DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. UROTHELIAL CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2030 (%)
FIGURE 18. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. UROTHELIAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. UROTHELIAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. UROTHELIAL CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NON PLATINUM BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PLATINUM BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ERDAFITINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ENFORTUMAB VEDOTIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY THIRD LINE OR LATER, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY METASTATIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY MUSCLE INVASIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NON MUSCLE INVASIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY HOSPITAL INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL UROTHELIAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 91. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 92. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 93. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 94. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 95. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 96. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 97. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 98. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 99. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 100. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2030 (USD MILLION)
TABLE 101. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 102. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 103. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 104. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 105. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 106. CANADA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 107. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 108. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 109. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 110. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 111. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 112. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 113. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 114. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 115. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 116. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2030 (USD MILLION)
TABLE 117. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 118. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 119. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 120. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 121. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 122. MEXICO UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 172. UNITED KINGDOM UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 176. UNITED KINGDOM UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 178. UNITED KINGDOM UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 180. UNITED KINGDOM UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2030 (USD MILLION)
TABLE 182. UNITED KINGDOM UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 188. GERMANY UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 189. GERMANY UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 190. GERMANY UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 191. GERMANY UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 192. GERMANY UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 193. GERMANY UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 194. GERMANY UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 195. GERMANY UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 196. GERMANY UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 197. GERMANY UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2030 (USD MILLION)
TABLE 198. GERMANY UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 199. GERMANY UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 200. GERMANY UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 201. GERMANY UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 202. GERMANY UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 203. GERMANY UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 204. FRANCE UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 205. FRANCE UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 206. FRANCE UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 207. FRANCE UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 208. FRANCE UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 209. FRANCE UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 210. FRANCE UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 211. FRANCE UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 212. FRANCE UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 213. FRANCE UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2030 (USD MILLION)
TABLE 214. FRANCE UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 215. FRANCE UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. FRANCE UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 217. FRANCE UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 218. FRANCE UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 219. FRANCE UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 220. RUSSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 221. RUSSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 222. RUSSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 223. RUSSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 224. RUSSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 236. ITALY UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 237. ITALY UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 238. ITALY UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 239. ITALY UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 240. ITALY UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 241. ITALY UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 242. ITALY UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 243. ITALY UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 244. ITALY UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 245. ITALY UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2030 (USD MILLION)
TABLE 246. ITALY UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 247. ITALY UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 248. ITALY UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 249. ITALY UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 250. ITALY UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 251. ITALY UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 252. SPAIN UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 253. SPAIN UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 254. SPAIN UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 255. SPAIN UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 256. SPAIN UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 257. SPAIN UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 258. SPAIN UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 259. SPAIN UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 260. SPAIN UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 261. SPAIN UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2030 (USD MILLION)
TABLE 262. SPAIN UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 263. SPAIN UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 264. SPAIN UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 265. SPAIN UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 266. SPAIN UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 267. SPAIN UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2030 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 284. SAUDI ARABIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 285. SAUDI ARABIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 286. SAUDI ARABIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 287. SAUDI ARABIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 288. SAUDI ARABIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 289. SAUDI ARABIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 290. SAUDI ARABIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 291. SAUDI ARABIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 292. SAUDI ARABIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 293. SAUDI ARABIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2030 (USD MILLION)
TABLE 294. SAUDI ARABIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 296. SAUDI ARABIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 298. SAUDI ARABIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 300. SOUTH AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 301. SOUTH AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 302. SOUTH AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 303. SOUTH AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 304. SOUTH AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 305. SOUTH AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 306. SOUTH AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 307. SOUTH AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 308. SOUTH AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY FGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 309. SOUTH AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY NECTIN-4 TARGETED, 2018-2030 (USD MILLION)
TABLE 310. SOUTH AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 312. SOUTH AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 314. SOUTH AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA UROTHELIAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 316. DENMARK UROTHELIAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 317. DENMARK UROTHELIAL CANCER DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2030 (USD MILLION)
TABLE 318. DENMARK UROTHELIAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 319. DENMARK UROTHELIAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 320. DENMARK UROTHE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Urothelial Cancer Drugs market report include:
  • Merck & Co., Inc.
  • Roche Holding AG
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Merck KGaA
  • Johnson & Johnson
  • Astellas Pharma Inc.
  • Seagen Inc.
  • Gilead Sciences, Inc.

Table Information

Report AttributeDetails
No. of Pages195
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.82 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.14 Billion
Compound Annual Growth Rate9.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Urothelial Cancer Drugs - Global Strategic Business Report - Product Image

Urothelial Cancer Drugs - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Urothelial Cancer Drugs Market Report 2025 - Product Image

Urothelial Cancer Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Advanced Urothelial Carcinoma - Pipeline Insight, 2025 - Product Image

Advanced Urothelial Carcinoma - Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From
Urothelial Carcinoma - Pipeline Insight, 2025 - Product Image

Urothelial Carcinoma - Pipeline Insight, 2025

  • Clinical Trials
  • 170 Pages
  • Global
From
America Cancer Immunotherapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

America Cancer Immunotherapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 110 Pages
  • Global
From

About the Urothelial Cell Carcinoma Drug Market

Urothelial Cell Carcinoma (UCC) is a type of cancer that affects the cells that line the urinary tract. Oncology drugs are used to treat UCC, and the UCC drug market is a subset of the larger oncology drug market. UCC drugs are typically divided into two categories: targeted therapies and immunotherapies. Targeted therapies are designed to target specific molecules or pathways that are involved in the growth and spread of cancer cells. Immunotherapies are designed to stimulate the body's own immune system to fight cancer cells. The UCC drug market is highly competitive, with many companies developing and marketing drugs for the treatment of UCC. Some of the major players in the market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. These companies are actively researching and developing new drugs to treat UCC, as well as marketing existing drugs to treat the disease. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.